IMW 2021 | Sustained MRD for treatment guidance in myeloma
Niels van de Donk
• 10 Sep 2021
Niels van de Donk, MD, PhD, of VU University Medical Center, Amsterdam, Netherlands, talks on the potential use of sustained measurable residual disease (MRD) to guide treatment as novel therapies and regimens are increasingly being employed in earlier settings. Prof. van de Donk explains that MRD may be a useful tool to help determine the duration of treatments; however, further research is required. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
Disclosures
Niels van de Donk, MD, PhD, has received research support from Janssen Pharmaceuticals, AMGEN, Celgene, Novartis and BMS; and serves in advisory boards for Janssen Pharmaceuticals, AMGEN, Celgene, BMS, Takeda, Roche, Novartis, Bayer, and Servier.
